A | AI摘要
7月末厦门本外币存贷款余额分别约2万亿和2.04万亿元，同比增6.3%和3.6%。 (ECNS) -- China's pharmaceutical industry accelerated innovation in the first half of this year, with domestic companies steadily improving their R&D capabilities and growth momentum continuing to strengthen, data showed. China's first broad-spectrum targeted anticancer drug entered clinical use at major hospitals across the country this year. It took only eight months to go from submission to market approval. A total of 38 innovative drugs were approved for marketing in China in the first half, of which 31 were developed domestically, more than 80% of the total. Eleven drugs featuring new targets or new mechanisms were all developed independently by domestic companies, producing a number of world-first innovations. By the end of 2025, China had 4,751 innovative drugs under development, one-third of the global total and the largest pipeline of any country. Behind this concentration of results lies a steadily strengthening industrial base. China has a complete pharmaceutical supply chain. It is not only the world's largest producer of active pharmaceutical ingredients but has also built a production system covering every pharmaceutical category. This year, digital, intelligent, and green technologies have driven the industry's transformation and upgrading. At a biopharmaceutical company in Shanxi Province, a newly built AI-powered bio-computing center can identify the structures of millions of protein functional domains in a short time, screening out ineffective molecules directly. To date, China has supported 21 pharmaceutical firms in building excellent-level smart factories and has cultivated more than 300 green factories. In the first half, the added value of pharmaceutical enterprises above the designated scale grew 6.4% year on year, and exports held strong. The world's first chemotherapy-sparing drug for gastric cancer, launched this year, had already earned overseas revenue through licensing deals before it reached the market, and is now exported to multiple countries and regions. In the first half, the total value of China's innovative drug out-licensing deals reached $110 billion, the industry's export delivery value grew 9% year on year, and high-value-added products made up nearly 20% of the total. (By Tang Yuxian) 
。
B | 前7月人民币存款增445亿元、贷款增387亿元；住户存款增而贷款减，企事业贷款增加，外币存贷增长较快。 人民银行厦门市分行日前发布2026年7月厦门市金融统计数据报告，报告显示，7月末，厦门市本外币存款余额19984.85亿元，同比增长6.3%，增速比上月末低1.6个百分点，比上年同期低2.7个百分点；人民币存款余额18939.96亿元，同比增长6.1%。
C | 今年前7月，厦门市人民币存款增加445.04亿元。其中，住户存款增加214.52亿元，非金融企业存款减少175.85亿元，财政性存款增加97.58亿元，非银行业金融机构存款增加286.24亿元。 7月末，厦门市外币存款余额153.9亿美元，同比增长15.1%。前7月外币存款增加11.22亿美元。
D | 7月末，厦门市本外币贷款余额20388.9亿元，同比增长3.6%，增速比上月末高0.2个百分点，比上年同期高0.8个百分点；人民币贷款余额19632.57亿元，同比增长2.7%。 前7月厦门市人民币贷款增加387.43亿元。分部门看，住户贷款减少82.9亿元，其中，短期贷款减少164.24亿元，中长期贷款增加81.33亿元；企（事）业单位贷款增加351.41亿元，其中，短期贷款增加140.48亿元，中长期贷款增加150.44亿元，票据融资增加53.66亿元；非银行业金融机构贷款减少42.4亿元。 7月末，厦门市外币贷款余额111.4亿美元，同比增长42.5%。前7月外币贷款增加46.46亿美元。（海峡导报记者 吴强）。
Current article:http://www.zhouangnaoguangsundianzhenmou.cfd/8f0c4k2/pgxj.html
Published on:14:41:43
